Compare Intuit Inc. (INTU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Intuit Inc. trades at $289.3 (market cap $80.37B), while Vertex Pharmaceuticals Incorporated trades at $478.11 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Intuit Inc. pays a 1.63% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| INTU | VRTX | |
|---|---|---|
Market Cap | $80.37B | $121.95B |
Sector | Technology | Health |
52-Week High | $807.39 | $529.59 |
52-Week Low | $255.07 | $366.54 |
Enterprise Value | $78.83B | $116.69B |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $291.09, down 1.26% over the past day, amid mixed technical signals and ongoing legal scrutiny. The stock shows strong fundamentals with revenue growth from $18.83B in 2025 to a projected $20.9B in 2026, net income margin improving to 21.91%, and consistent earnings beats. However, recent news highlights a 20% stock drop and multiple securities fraud investigations related to TurboTax pricing issues, creating investor uncertainty despite a bullish analyst consensus.
The outlook for INTU is cautiously optimistic given its robust financial health and AI-driven growth initiatives, but near-term risks from legal challenges and market sentiment could pressure the stock. Investors should weigh the company's solid profitability and upward earnings trajectory against potential volatility from ongoing investigations and competitive pressures in the fintech software space.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
